DEHP phthalates in medical devices

AI Summary

This regulatory guidance issued by the UK Medicines and Healthcare products Regulatory Agency (MHRA) details the safety expectations and legal requirements for medical devices containing phthalates, specifically Di(2-ethylhexyl) phthalate (DEHP). Phthalates are commonly used as plasticizers to enhance the flexibility of materials like polyvinyl chloride (PVC); however, they present significant safety concerns due to their potential for leaching and subsequent toxic effects on human development and reproduction. Operating under the UK Medical Devices Regulations 2002, the framework mandates that manufacturers must provide a rigorous justification if phthalates are present in concentrations above 0.1% by weight. Key actions required include performing a comprehensive risk-benefit analysis, evaluating safer alternatives, and adhering to strict labeling requirements that clearly identify the presence of these substances. Although this document represents general agency policy rather than a specific company inspection report with specific dates, it serves as a critical directive for all manufacturers to mitigate patient exposure risks. Special attention is directed toward devices used for vulnerable groups, such as infants and pregnant women, where the use of phthalate-free alternatives is strongly encouraged to ensure compliance with modern safety standards.